Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous CD34+ stem cells
- Development stage
- Unknown
- Lead developer
- University of California, Davis
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Ophthalmic
01
Overview
This is an investigational autologous cell therapy being developed by the University of California, Davis for the treatment of retinitis pigmentosa (RP). The active ingredient consists of autologous CD34+ stem cells isolated from the patient's own bone marrow. The therapy involves a same-day procedure where bone marrow is aspirated from the patient's iliac crest, CD34+ cells are isolated under Good Manufacturing Practice conditions at the UC Davis Institute for Regenerative Cures using a Ficoll density gradient and the Miltenyi CliniMACS system, and then the isolated cells are administered via intravitreal injection into the affected eye. The therapy is believed to work through the CD34+ cells' ability to home to damaged retinal tissue and potentially generate molecular changes to reduce photoreceptor degeneration. A Phase I clinical trial (BMSCRP1) demonstrated that the therapy is feasible and well-tolerated, with some patients showing improvements in visual function.
- Other names
- Intravitreal autologous CD34+ cellsautologous bone marrow CD34+ stem cell therapy
Beyond the preview
Go deeper on autologous CD34+ stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous CD34+ stem cells.